Factors associated with intensification of antihypertensive drug therapy in patients with poorly controlled hypertension.

药品 氨氯地平 血管紧张素受体阻滞剂 心脏病学 氢氯噻嗪
作者
O. Siga,Barbara Wizner,Barbara Gryglewska,J. Walczewska,Tomasz Grodzicki
出处
期刊:Journal of Geriatric Cardiology [Science Press]
卷期号:16 (1): 19-26 被引量:1
标识
DOI:10.11909/j.issn.1671-5411.2019.01.001
摘要

Objective To assess antihypertensive management of older patients with poor blood pressure (BP) control. Methods Physicians, voluntary participating in the study, included six consecutive hypertensive patients during routine visits. Hypertension had to have been previously recognized and averaged office BP was ≥ 140 and/or ≥ 90 mmHg in spite of ≥ 6 weeks of antihypertensive therapy. The physicians completed a questionnaire on patients' history of cardiovascular (CV) risk factors, comorbidities, home BP monitoring, anthropometric data and the pharmacotherapy. Results Mean age of the 6462 patients was 61 years, 7% were ≥ 80 years, 51% were female. Mean ± SD office BP values were 158 ± 13/92 ± 10 mmHg. The most commonly prescribed antihypertensive drugs were: diuretics (67%), ACE inhibitors (64%), calcium channel blockers (58%) and β-blockers (54%), and their use increased with age. On monotherapy or dual therapy, 43% of the patients and 40% had their latest treatment modification within six months. Home BP monitoring was a factor that accelerated the modification of the therapy. Older patients had to have less chance on faster modification of antihypertensive therapy in spite of presence of diabetes and higher systolic BP. Conclusions Our study suggests that a large number of outpatients with poor BP control receive suboptimal antihypertensive therapy, especially in primary care. In older patients, higher BP values in the office settings are more frequently accepted by physicians even in case of higher CV risk. Regular home BP monitoring hastens the decision to intensify of antihypertensive treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
feifei发布了新的文献求助10
1秒前
思源应助xiaon采纳,获得10
2秒前
无花果应助ggjy采纳,获得20
2秒前
孤独孤风完成签到,获得积分10
3秒前
wyn发布了新的文献求助10
3秒前
3秒前
科研通AI5应助成就的焦采纳,获得10
3秒前
科研通AI5应助单薄的南蕾采纳,获得10
4秒前
4秒前
5秒前
温壹完成签到,获得积分10
5秒前
小白完成签到,获得积分10
6秒前
干净三德完成签到,获得积分20
6秒前
wanci应助勤奋冰烟采纳,获得10
6秒前
TG_FY完成签到,获得积分10
7秒前
wbhou完成签到 ,获得积分10
7秒前
AA完成签到,获得积分10
7秒前
半颜发布了新的文献求助20
7秒前
llll发布了新的文献求助10
7秒前
7秒前
李文思完成签到,获得积分10
8秒前
不倦应助linl采纳,获得10
8秒前
今后应助BakedMax采纳,获得10
8秒前
HY完成签到,获得积分10
9秒前
9秒前
芳芳完成签到,获得积分10
10秒前
cc123完成签到,获得积分10
11秒前
Mry完成签到,获得积分10
11秒前
ZCX完成签到,获得积分10
12秒前
云中丽景发布了新的文献求助10
12秒前
Frank发布了新的文献求助10
12秒前
666完成签到,获得积分10
13秒前
纯真涵菱发布了新的文献求助10
13秒前
一只菠萝包关注了科研通微信公众号
14秒前
爱笑的蘑菇完成签到,获得积分10
14秒前
CC完成签到,获得积分20
14秒前
马良完成签到,获得积分10
15秒前
Orange应助海绵宝宝采纳,获得10
16秒前
成就的焦完成签到,获得积分10
17秒前
舟舟完成签到 ,获得积分10
18秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Izeltabart tapatansine - AdisInsight 800
Maneuvering of a Damaged Navy Combatant 650
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3773860
求助须知:如何正确求助?哪些是违规求助? 3319480
关于积分的说明 10195353
捐赠科研通 3034172
什么是DOI,文献DOI怎么找? 1664936
邀请新用户注册赠送积分活动 796406
科研通“疑难数据库(出版商)”最低求助积分说明 757443